Winton Group’s Crescent Biopharma CBIO Stock Holding History

Winton Group’s Portfolio CBIO Stock Details CBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-111	Closed	-$105K	–	1112
2018 Q4	$105K	Sell	111 -18	-14%	-$21.7K	﹤0.01%	838
2018 Q3	$186K	Buy	+129	New	+$195K	﹤0.01%	980

Other funds holding CBIO

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Winton Group's CBIO Position: Q1 2019 in Review

Winton Group sold out of Crescent Biopharma (CBIO) in Q1 2019, closing a stake of 111 shares — an estimated $105K sold.

Winton Group first reported a position in CBIO in Q3 2018 and held it in 2 quarters. The position peaked at $186K in Q3 2018. 77 funds tracked by Wall St. Rank hold CBIO as of Q1 2019.

Winton Group reported no remaining Crescent Biopharma position as of Q1 2019 after selling out during the quarter.
Winton Group sold 111 Crescent Biopharma shares in Q1 2019, an estimated $105K.
Winton Group first reported a position in Crescent Biopharma in Q3 2018 and held it in 2 quarters.
Winton Group's Crescent Biopharma position peaked at $186K in Q3 2018.
77 funds tracked by Wall St. Rank held Crescent Biopharma as of Q1 2019.

Based on Winton Group's 13F filing for Q1 2019, filed 13 May 2019.